Clinical Trials Logo

Clinical Trial Summary

Establishment and validation of the deep learning model of Cetuximab efficacy in simultaneous RAS wild unresectable CRLM patients


Clinical Trial Description

Ras wild unresectable CRLM patients with primary tumor resection followed by Cetuximab in combination with chemotherapy were included in this study. The tumor response was assessed by local MDT group. Based on tumor response, almost 100 CRLM patients were classified into two groups (Clinician drived regimen vs Multi-omics model drived regimen). They will be the prospective cohort to validate our deep learning model for predicting Cetuximab efficacy. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05873972
Study type Interventional
Source Fudan University
Contact Jianmin Xu, MD
Phone +86-021-64041990
Email xujmin@aliyun.com
Status Not yet recruiting
Phase N/A
Start date June 1, 2023
Completion date December 31, 2024

See also
  Status Clinical Trial Phase
Not yet recruiting NCT05588297 - Preoperative Nivolumab Plus Bevacizumab Combined With Chemotherapy Before Surgery in Patients With pMMR/MSS Colorectal Cancer Liver Metastases Phase 2
Active, not recruiting NCT04272931 - DRAGON 1- Training, Accreditation, Implementation and Safety Evaluation of Combined PVE/HVE N/A
Completed NCT02086656 - PERIOPERATIVE TREATMENT WITH COI-B (CAPECITABINE, OXALIPLATIN, IRINOTECAN AND BEVACIZUMAB) OF HIGH RISK OR BORDERLINE RESECTABLE COLORECTAL CANCER LIVER METASTASES Phase 2
Recruiting NCT05794971 - Regorafenib Combined With Irinotecan Drug-Eluting Beads for Colorectal Cancer Liver Metastases Phase 3
Recruiting NCT05485909 - Phase II Study of Regorafenib and Toripalimab Combined With RFA in Patients With CRCLM Phase 2
Active, not recruiting NCT03326791 - Aspirin in Colorectal Cancer Liver Metastases Phase 2/Phase 3